Chronic rhinosinusitis with nasal polyps (CRSwNP) is a minor indication for GSK’s depemokimab compared with its commercial potential in asthma. Nonetheless, the market is worth contesting, and the topline Phase III hit the UK group disclosed on 14 October could enable it to carve out share from occupants including Dupixent.
Key Takeaways
- GSK’s anti-IL-5 antibody depemokimab has succeeded in the twin ANCHOR-1 and -2 studies in chronic rhinosinusitis with nasal polyps, though only the topline hit has been revealed so far.
- A look at the data on approved products such as Dupixent and Nucala indicate the goals for when the full data come out
However, depemokimab has itself set an uneasy precedent. Its pivotal asthma trial was revealed as a success in May, but disclosure of the full data four months later revealed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
